Eli Lilly stated its weight-loss drug Zepbound outperformed rival Novo Nordisk’s Wegovy within the first head-to-head trial of the 2 blockbusters. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke to Bloomberg TV in regards to the outcomes https://trib.al/Y3suGBA
